Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
Frontiers in Cell and Developmental Biology · 15.09.2023 · 11
DOI: 10.3389/fcell.2023.1176657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 15.09.2023. Verfasst von Christine Parseghian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The development of acquired resistance to anti-EGFR therapies remains poorly understood, with most research to date exploring, and trying to overcome, various genomic mechanisms of resistance. However, recent work supports a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with anti-EGFR therapy in the first-line setting, with a greater predominance of acquired MAPK mutations after single-agent anti-EGFR therapy in the later-line setting. The proposed model has implications for prospective studies evaluating anti-EGFR rechallenge strategies guided by acquired MAPK mutations and highlights the need to address transcriptional mechanisms of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Zitieren
APA
Parseghian, C., Eluri, M., Kopetz, S., & Raghav, K. (2023). Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1176657
Vancouver
Parseghian C, Eluri M, Kopetz S, Raghav K. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1176657
BibTeX
@article{Parseghian2023,
author = {Parseghian, Christine and Eluri, Madhulika and Kopetz, Scott and Raghav, Kanwal},
title = {Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics},
journal = {Frontiers in Cell and Developmental Biology},
year = {2023},
volume = {11},
doi = {10.3389/fcell.2023.1176657}
}
EUVIMED